Exercise Testing and Exercise Rehabilitation for Patients With Atrial Fibrillation.


Journal

Journal of cardiopulmonary rehabilitation and prevention
ISSN: 1932-751X
Titre abrégé: J Cardiopulm Rehabil Prev
Pays: United States
ID NLM: 101291247

Informations de publication

Date de publication:
03 2019
Historique:
entrez: 26 2 2019
pubmed: 26 2 2019
medline: 28 5 2020
Statut: ppublish

Résumé

Atrial fibrillation (AF) is a common cardiac arrhythmia associated with an increasing prevalence with advancing age. It is associated with dyspnea, exercise intolerance, and increased risk for clinical events, especially stroke and heart failure. This article provides a concise review of exercise testing and rehabilitation in patients with persistent or permanent AF. The first goal in the treatment of AF is to reduce symptoms (eg, palpitations) and a fast ventricular rate. The second goal is to reduce the risk of a stroke. Exercise testing and rehabilitation may be useful once these goals are achieved. However, there are no large, randomized exercise training trials involving patients with AF, and what data are available comes from single-site trials, secondary analyses, and observational studies. There are no specific indications for performing a graded exercise test in patients with AF; however, such testing may be used to screen for myocardial ischemia or evaluate chronotropic response during exertion. Among patients with AF, exercise capacity is 15% to 20% lower and peak heart rate is higher than in patients in sinus rhythm. Exercise rehabilitation improves exercise capacity, likely improves quality of life, and may improve symptoms associated with AF. Whole-body aerobic exercise is recommended. Atrial fibrillation is a common cardiac condition and in these patients, exercise rehabilitation favorably improves exercise capacity. However, prospective randomized controlled trials are needed to better define the effects of exercise training on safety; quality of life; clinical outcomes; and central, autonomic, and peripheral adaptations.

Identifiants

pubmed: 30801433
doi: 10.1097/HCR.0000000000000423
pii: 01273116-201903000-00001
pmc: PMC6394874
mid: NIHMS1517511
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

65-72

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL135440
Pays : United States

Références

BMJ. 2016 Sep 06;354:i4482
pubmed: 27599725
Cochrane Database Syst Rev. 2017 Feb 09;2:CD011197
pubmed: 28181684
J Cardiopulm Rehabil Prev. 2018 May;38(3):139-146
pubmed: 29697494
J Cardiovasc Electrophysiol. 2003 Sep;14(9 Suppl):S52-5
pubmed: 12950519
Heart Lung. 1992 Sep-Oct;21(5):427-33
pubmed: 1399661
Can J Cardiol. 2013 Apr;29(4):483-91
pubmed: 23200094
Curr Opin Cardiol. 2014 Sep;29(5):475-80
pubmed: 25010379
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
J Cardiopulm Rehabil. 1996 May-Jun;16(3):193-6
pubmed: 8761840
Int J Cardiol. 2007 Mar 2;116(1):86-92
pubmed: 16815571
J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76
pubmed: 24685669
Eur J Prev Cardiol. 2013 Apr;20(2):376-82
pubmed: 22345697
J Cardiopulm Rehabil Prev. 2008 Jan-Feb;28(1):24-30; quiz 31-2
pubmed: 18277826
J Cardiopulm Rehabil. 2006 Mar-Apr;26(2):72-5; quiz 76-7
pubmed: 16569971
Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):85-93
pubmed: 22235070
J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975
pubmed: 29103847
Can J Cardiol. 2018 Apr;34(4):429-436
pubmed: 29455950
Int J Cardiol Heart Vasc. 2018 Feb 18;18:25-29
pubmed: 29556526
JAMA Cardiol. 2018 May 1;3(5):409-416
pubmed: 29562087
Circulation. 2007 Jul 31;116(5):572-84
pubmed: 17638929
Int J Cardiol. 2012 Nov 1;161(1):39-44
pubmed: 21570138
Can J Cardiol. 2013 Dec;29(12):1721-8
pubmed: 24267810
J Am Coll Cardiol. 2017 Apr 4;69(13):1683-1691
pubmed: 28359513
Mayo Clin Proc. 2010 Dec;85(12):1095-100
pubmed: 21123636
J Cardiovasc Electrophysiol. 2018 May;29(5):747-755
pubmed: 29364570
Am Heart J. 2007 Apr;153(4):566-72
pubmed: 17383295
N Engl J Med. 2012 Jan 12;366(2):120-9
pubmed: 22236222
J Am Coll Cardiol. 1988 Mar;11(3):508-13
pubmed: 3343453
Circulation. 2013 Aug 20;128(8):873-934
pubmed: 23877260
J Am Coll Cardiol. 2015 Sep 1;66(9):985-96
pubmed: 26113406
CMAJ. 2014 Oct 7;186(14):E558
pubmed: 25002561
Clin Res Cardiol. 2008 Nov;97(11):820-6
pubmed: 18648726
Am Heart J. 2011 Dec;162(6):1080-7
pubmed: 22137082
Am Heart J. 2016 Mar;173:49-56
pubmed: 26920596
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358
Circulation. 2016 Feb 2;133(5):466-73
pubmed: 26733609
Circulation. 1968 Apr;37(4):543-8
pubmed: 5649079
J Cardiopulm Rehabil. 2000 Nov-Dec;20(6):346-52
pubmed: 11144040
Heart. 1997 Dec;78(6):564-8
pubmed: 9470871
Am Heart J. 2016 Nov;181:120-129
pubmed: 27823683
Heart Rhythm. 2017 Nov;14(11):1713-1720
pubmed: 28694186

Auteurs

Steven J Keteyian (SJ)

Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan (Drs Keteyian, Ehrman, and Fuller); and Division of Cardiovascular Medicine, Baystate Medical Center, Springfield, Massachusetts (Dr Pack).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH